Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.

about

Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.

Item

http://www.wikidata.org/entity/Q38048837

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Role of genotype-based persona ...... ent P2Y₁₂ receptor inhibitors.

@en

type

Item

label

Role of genotype-based persona ...... ent P2Y₁₂ receptor inhibitors.

@en

prefLabel

Role of genotype-based persona ...... ent P2Y₁₂ receptor inhibitors.

@en

P1476

Role of genotype-based persona ...... ent P2Y₁₂ receptor inhibitors.

@en

P2093

Kevin P Bliden

http://www.w3.org/2001/XMLSchema#string

Mark J Antonino

http://www.w3.org/2001/XMLSchema#string

Paul A Gurbel

http://www.w3.org/2001/XMLSchema#string

Udaya S Tantry

http://www.w3.org/2001/XMLSchema#string

Young-Hoon Jeong

http://www.w3.org/2001/XMLSchema#string

P2860

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment el

Central role of the P2Y12 receptor in platelet activation

Antiplatelet therapy for ischemic heart disease

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study

Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Genotyping: one piece of the puzzle to personalize antiplatelet therapy.

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.

P304

1011-1022

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERC.12.1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23030291

http://www.w3.org/2001/XMLSchema#string